<?xml version="1.0" encoding="UTF-8"?>
<results title="drug">
 <result pre="Lopinavirâ€&quot;ritonavir Lopinavirâ€&quot;ritonavir is a combination therapy used to treat HIV." exact="Ritonavir" post="is an inhibitor of cytochrome P450 and is used"/>
 <result pre="gastrointestinal intolerance, hepatotoxicity, pancreatitis, and QT prolongation. The use of" exact="ritonavir" post="can cause severe drugâ€&quot;drug interactions in medications metabolised through"/>
 <result pre="lopinavirâ€&quot;ritonavir combined with different drugs and different combinations such as" exact="ritonavir" post="and interferon 1b.39,56 Early use of lopinavirâ€&quot;ritonavir as an"/>
 <result pre="trial is ongoing and results have yet to be published.60" exact="Ribavirin" post="Ribavirin is a guanosine analogue that interferes with the"/>
 <result pre="is ongoing and results have yet to be published.60 Ribavirin" exact="Ribavirin" post="is a guanosine analogue that interferes with the replication"/>
 <result pre="replication of RNA and DNA viruses.61In vitro antiviral activities of" exact="Ribavirin" post="have been demonstrated in SARS-CoV and MERS-CoV.61,62 From the"/>
 <result pre="and MERS-CoV.61,62 From the experiences of SARS-CoV, the use of" exact="ribavirin" post="as a monotherapy was limited as it required high"/>
 <result pre="as it required high concentration to inhibit viral replication, and" exact="ribavirin" post="usage was associated with dose-dependent haemolysis and liver toxicity.63,64"/>
 <result pre="and liver toxicity.63,64 In the treatment of SARS and MERS," exact="ribavirin" post="is used in combination with interferon or lopinavir/ritonavir.11,65 The"/>
 <result pre="used in combination with interferon or lopinavir/ritonavir.11,65 The use of" exact="ribavirin" post="in combination with interferon or lopinavir/ritonavir is recommended in"/>
 <result pre="viral shedding and hospital stay in patients with mild-to-moderate COVID-19.67" exact="Chloroquine" post="and hydroxychloroquine Chloroquine and hydroxychloroquine are widely used for"/>
 <result pre="and hospital stay in patients with mild-to-moderate COVID-19.67 Chloroquine and" exact="hydroxychloroquine" post="Chloroquine and hydroxychloroquine are widely used for the treatment"/>
 <result pre="hospital stay in patients with mild-to-moderate COVID-19.67 Chloroquine and hydroxychloroquine" exact="Chloroquine" post="and hydroxychloroquine are widely used for the treatment of"/>
 <result pre="in patients with mild-to-moderate COVID-19.67 Chloroquine and hydroxychloroquine Chloroquine and" exact="hydroxychloroquine" post="are widely used for the treatment of malaria and"/>
 <result pre="safety profile and are readily available at relatively low cost." exact="Hydroxychloroquine" post="sulphate has been demonstrated to be less toxic than"/>
 <result pre="Hydroxychloroquine sulphate has been demonstrated to be less toxic than" exact="chloroquine" post="phosphate in animal studies.68 Both these drugs have been"/>
 <result pre="China involving more than 100 patients with Covid-19 showed that" exact="chloroquine" post="was better able to inhibit exacerbation of pneumonia and"/>
 <result pre="recent small open-label nonrandomised clinical trial showed patients given daily" exact="hydroxychloroquine" post="had significantly reduced viral load measured by nasopharyngeal swab"/>
 <result pre="factors, as some patients also received azithromycin.71 The combination of" exact="hydroxychloroquine" post="and azithromycin should be used with caution in patients"/>
 <result pre="some patients also received azithromycin.71 The combination of hydroxychloroquine and" exact="azithromycin" post="should be used with caution in patients at risk"/>
 <result pre="in patients at risk for QT prolongation. The use of" exact="chloroquine" post="alone is also a risk factor for QT prolongation."/>
 <result pre="IIb clinical trial assessing the safety and efficacy of high-dose" exact="chloroquine" post="was terminated early due to prolonged QTc (&amp;gt;500 ms)"/>
 <result pre="a multinational registry of 96,032 hospitalised COVID-19 patients revealed that" exact="hydroxychloroquine" post="or chloroquine was associated with decreased in-hospital survival (mortality"/>
 <result pre="registry of 96,032 hospitalised COVID-19 patients revealed that hydroxychloroquine or" exact="chloroquine" post="was associated with decreased in-hospital survival (mortality of 11.1"/>
 <result pre="led to retraction of the article.74 Other adverse effects of" exact="chloroquine" post="include retinopathy, rash, nausea, glucose fluctuation and diarrhoea, and"/>
 <result pre="retinopathy, rash, nausea, glucose fluctuation and diarrhoea, and use of" exact="chloroquine" post="is contraindicated in patients with porphyria. Chloroquine or hydroxychloroquine"/>
 <result pre="and use of chloroquine is contraindicated in patients with porphyria." exact="Chloroquine" post="or hydroxychloroquine should not be used to treat COVID-19"/>
 <result pre="of chloroquine is contraindicated in patients with porphyria. Chloroquine or" exact="hydroxychloroquine" post="should not be used to treat COVID-19 until they"/>
 <result pre="to determine the optimal dosage to balance efficacy and safety." exact="Chloroquine" post="or hydroxychloroquine has been suggested as candidate prophylactics for"/>
 <result pre="the optimal dosage to balance efficacy and safety. Chloroquine or" exact="hydroxychloroquine" post="has been suggested as candidate prophylactics for COVID-19 in"/>
 <result pre="for COVID-19 currently undergoing clinical trials include protease inhibitors (nelfinavir," exact="camostat" post="mesilate, ritonavir, danoprevir, darunavir, flavopiridol, relacatib), nucleoside analogues (galidesivir),"/>
 <result pre="targeting the immune system Corticosteroids Corticosteroid therapies such as intravenous" exact="methylprednisolone" post="are currently being tested as a treatment for COVID-19.77"/>
 <result pre="methylprednisolone are currently being tested as a treatment for COVID-19.77" exact="Methylprednisolone" post="has already been used in COVID-19 patients in combination"/>
 <result pre="and colleagues reported that corticosteroid therapy using methylprednisolone, dexamethasone, and" exact="hydrocortisone" post="was beneficial in treating SARS-CoV patients,78 and significantly prolonged"/>
 <result pre="treated with a combination therapy of moxifloxacin, lopinavir, interferon, and" exact="methylprednisolone" post="(given to only ICU patients) showed good treatment effects"/>
 <result pre="case report of a 45-year-old woman with COVID-19 treated with" exact="thalidomide" post="(100 mg orally once a day) and methylprednisolone (40"/>
 <result pre="treated with thalidomide (100 mg orally once a day) and" exact="methylprednisolone" post="(40 mg intravenously bid for 3 days then reduced"/>
 <result pre="option for the COVID-19Travel Med Infect Dis202010.1016/j.tmaid.2020.101615 45WangMCaoRZhangLet al.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
 <result pre="replication in vitroAntiviral Res2020178March10478610.1016/j.antiviral.2020.10478632251767 56collab: US National Library of MedicineLopinavir/ritonavir," exact="ribavirin" post="and IFN-beta combination for nCoV treatmenthttps://clinicaltrials.gov/ct2/show/NCT04276688. Published 2020Accessed April"/>
 <result pre="17, 2020 67HungIF-NLungK-CTsoEY-Ket al.Triple combination of interferon beta-1b, lopinavirâ€&quot;ritonavir, and" exact="ribavirin" post="in the treatment of patients admitted to hospital with"/>
 <result pre="open-label, randomised, phase 2 trialLancet202010.1016/S0140-6736(20)31042-4 68McChesneyEWAnimal toxicity and pharmacokinetics of" exact="hydroxychloroquine" post="sulfateAm J Med1983751 PART 1111810.1016/0002-9343(83)91265-26408923 69CortegianiAIngogliaGIppolitoMGiarratanoAEinavSA systematic review on"/>
 <result pre="1111810.1016/0002-9343(83)91265-26408923 69CortegianiAIngogliaGIppolitoMGiarratanoAEinavSA systematic review on the efficacy and safety of" exact="chloroquine" post="for the treatment of COVID-19J Crit Care20203710.1016/j.jcrc.2020.03.005 70GaoJTianZYangXBreakthrough: chloroquine"/>
 <result pre="of chloroquine for the treatment of COVID-19J Crit Care20203710.1016/j.jcrc.2020.03.005 70GaoJTianZYangXBreakthrough:" exact="chloroquine" post="phosphate has shown apparent efficacy in treatment of COVID-19"/>
 <result pre="COVID-19 associated pneumonia in clinical studiesBiosci Trends2020141727310.5582/bst.2020.0104732074550 71GautretPLagierJ-CParolaPet al.Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
 <result pre="results of a randomized, double-blinded, phase IIb clmedRxiv202010.1101/2020.04.07.20056424 73MehraMRDesaiSSRuschitzkaFPatelANHydroxychloroquine or" exact="chloroquine" post="with or without a macrolide for treatment of COVID-19:"/>
 <result pre="for treatment of COVID-19: a multinational registry analysisLancet202010.1016/S0140-6736(20)31180-6 74MehraMRRuschitzkaFPatelANRetraction-Hydroxychloroquine or" exact="chloroquine" post="with or without a macrolide for treatment of COVID-19:"/>
 <result pre="macrolide for treatment of COVID-19: a multinational registry analysisLancet202010.1016/S0140-6736(20)31324-6 75PrincipiNEspositoSCorrespondence" exact="chloroquine" post="or hydroxychloroquine for prophylaxis of COVID-19Lancet Infect Dis20203099203029610.1016/S1473-3099(20)30296-6 76collab:"/>
 <result pre="treatment of COVID-19: a multinational registry analysisLancet202010.1016/S0140-6736(20)31324-6 75PrincipiNEspositoSCorrespondence chloroquine or" exact="hydroxychloroquine" post="for prophylaxis of COVID-19Lancet Infect Dis20203099203029610.1016/S1473-3099(20)30296-6 76collab: World Health"/>
 <result pre="US National Library of MedicineOutcomes related to COVID-19 treated with" exact="hydroxychloroquine" post="among in-patients with symptomatic diseasehttps://clinicaltrials.gov/ct2/show/NCT04332991. Published 2020Accessed April 19,"/>
 <result pre="19, 2020 114collab: US National Library of MedicineThe impact of" exact="camostat" post="mesilate on COVID-19 infection (CamoCO-19)https://clinicaltrials.gov/ct2/show/NCT04321096?term=camostat+mesilate&amp;amp;cond=COVID&amp;amp;draw=2&amp;amp;rank=4. Published 2020Accessed April 22,"/>
 <result pre="Library of MedicineVarious combination of protease inhibitors, oseltamivir, favipiravir, and" exact="hydroxychloroquine" post="for treatment of COVID-19: a randomized control trial (THDMS-COVID-19)"/>
 <result pre="mg PO daily for 5 days QT prolongationNausea and vomitingRetinopathyRashHypoglycaemia" exact="Hydroxychloroquine" post="sulfate64,113 Adult: 400 mg PO every 12 hours for"/>
 <result pre="PO every 12 hours for 4 days. Protease inhibitor76,114â€&quot;116 Nelfinavir," exact="camostat" post="mesilate, ritonavir, danoprevir, darunavir, flavopiridol, relacatib PO LipodystrophyMetabolic effects"/>
 <result pre="side effectsHeadache Pharmacological therapies targeting the immune system Corticosteroids66,77,110,120 Adult:" exact="methylprednisolone" post="40 mg IV every 12 hours for 5 days"/>
 <result pre="annua 12 g, Polygonum cuspidatum 20 g, verbena 30 g," exact="dried" post="reed root 30 g, gardenia 15 g, orange red"/>
</results>
